Skip to content

Toi Même: a Mobile System for Measuring Bipolar Illness

Toi Même: a Mobile System for Measuring Bipolar Illness Activity - Feasibility Study

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03508427
Enrollment
36
Registered
2018-04-25
Start date
2018-04-12
Completion date
2020-12-31
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder

Keywords

Bipolar Disorder, Smartphone, Self-monitoring, Objective data

Brief summary

Bipolar disorder is a severe psychiatric illness with chronic course and it is associated with high risk of relapse and hospitalisation, and many patients do not recover to their previous psychosocial functioning. Major reasons for poor outcomes are delayed intervention for prodromal mood and behavioural symptoms as well as incomplete treatment responses. Current diagnostic approaches used to assess mood symptoms rely on symptom-based categories, which lack sensitivity to detect subtle mood and behavioural changes. Therefore, the ability to better characterizing bipolar patients may allow to detect possible differences in the illness activity. On the other hand, there is a growing interest in the potential use of mobile technologies such as mobile apps, smartphone and internet in psychiatric care. Some projects have been testing the potential benefits of mobile apps to assess and treat individuals at-risk or suffering from mood and bipolar disorders, using online signs and symptoms monitoring, yet to the investigators knowledge, none of them have integrated a dimensional approach in a smartphone app to assess mood and behavioural alterations and bipolar illness activity, including subjective and objective data (e.g. physical activity, social activity, etc.). In this feasibility study the investigators will evaluate the potential relevance of Toi Même app to self-monitoring mood and behavioural changes in bipolar patients with different mood phases compared to the gold-standard mood rating tools used in clinical practice. All patients will be followed for 3 months, with outcome assessments after 2 weeks, after 1 month, 2 months and after 3 months.

Interventions

OTHERDaily self-monitoring

Toi Même self-monitoring smartphone application plus treatment as usual which includes pharmacological and/or psychological treatment.

Sponsors

Institut Pasteur
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

One-arm study

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* patients with the current diagnosis of Bipolar disorder type I or type II according to the DSM-5 criteria * having an iPhone with iOS version from 9.x with access to wireless Internet connectivity.

Exclusion criteria

* Current DSM-5 diagnosis of schizophrenia, psychotic disorders, dementia, or mental retardation. * Active suicidal ideation or behaviours.

Design outcomes

Primary

MeasureTime frameDescription
Severity of depressive symptoms3 months study periodChanges in depressive symptoms measured using the Montgomery-Asberg Depression Rating Scale during the 3 months study period.
Severity of manic symptoms3 months study periodChanges in manic symptoms measured using the Young Mania Rating Scale during the 3 months study period.

Secondary

MeasureTime frameDescription
Activation levels3 months study periodChanges in levels of activation measured using the scale Multidimensional Assessment of Thymic States (MAThyS) during the 3 months study period.
Treatment adherence3 months study periodDifferences in treatment adherence using the 10-item Medication Adherence Rating Scale (MARS) during the 3 months study period.
Functional impairment3 months study periodDifferences in functional impairment using the Functioning Assessment Short Test (FAST) during the 3 months study period.
Self-rated depressive symptoms3 months study periodDifferences in self-rated depressive symptom using the Quick Inventory of Depressive Symptomatology (QIDS) during the 3 months study period.
Completion rate3 months study period.Differences in the completion rate of app self-assessment questionnaires.
Patient acceptance3 months study period.Patient acceptance rate measured by a questionnaire
Movement behavior3 months study period.Differences in movement behavior using the smartphone motion sensors during the 3 months study period.
Self-rated manic symptoms3 months study periodDifferences in self-rated manic symptoms using the Altman Mania Self-Rating Scale (ASRM) during the 3 months study period.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026